Ultragenyx Pharmaceutical Inc. Announces FDA Accelerated Approval of GENGLYCOS

What Happened

• On August 19, 2026, Ultragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr; DTX401) for adult and pediatric patients aged eight years and older with glycogen storage disease type Ia (GSDIa).
• The approval is based on positive results from the Phase 3 GlucoGene study (48-week, randomized, double‑blind, placebo‑controlled) in which 46 participants received DTX401 or placebo; the modified intention-to-treat (mITT) population included 44 participants (DTX401 n=20; placebo n=24). At the tested dose (1.0 x 10^13 GC/kg), treated patients showed a statistically significant reduction in cornstarch requirements (p<0.001).

Key Details

• FDA action date announced: August 19, 2026.
• Phase 3 GlucoGene: 48-week randomized, double‑blind, placebo‑controlled; follow-up assessments extended to Week 96 and Week 144 after crossover at Week 48.
• Dose studied: 1.0 x 10^13 GC/kg; mITT efficacy population: 44 participants (20 treated, 24 placebo).
• Post‑marketing commitments: Ultragenyx will provide two years of safety and efficacy data from open‑label commercial treatment of 50 GENGLYCOS-treated patients and 20 control patients via an enhanced Disease Monitoring Program (DMP); the DMP will follow trial and commercial patients for up to 10 years. The control group will include patients who cannot be treated due to anti‑AAV8 antibodies.

Why It Matters

• FDA accelerated approval allows Ultragenyx to commercially market GENGLYCOS for GSDIa in patients ≥8 years while the company completes post‑marketing data collection, potentially enabling near‑term revenue from this therapy.
• The approval was granted on the basis of measured clinical benefit in reducing cornstarch dependence in the trial; continued access and full approval will depend on the results of the required post‑marketing monitoring (the DMP) and data from the specified cohorts.